Factors Influencing the Response to Interferon Therapy in Chronic Hepatitis C Studies on Viral Genotype and Induction of 2′,5′-Oligoadenylate Synthetase in the Liver and Peripheral Blood Cells

References

• Dienstag J. Non‐A, non‐B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439–62
   PubMed Web of Science ®Google Scholar
• Weiland O. Interferon therapy in chronic hepatitis C virus infection. FEMS Microbiol Rev 1994; 14: 279–88
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Giostra E, Degott C, Courouce A, Degos F, et al. Recombinant human alfa‐interferon in patients with chronic non‐A, non‐B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–7
   PubMed Web of Science ®Google Scholar
• Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543
   PubMed Web of Science ®Google Scholar
• Yun Z B, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C—importance for outcome of interferon alfa‐2b treatment. Scand J Infect Dis 1994; 26: 263–70
   PubMed Web of Science ®Google Scholar
• Lengyel P. Mechanisms of interferon action: the (2',5') (A)n synthetase‐RNase L pathway, I Gresser. Academic Press, London 1981; 78–99, Interferon
   Google Scholar
• Kerr I M, Brown R E. PppA2' p5' A2'‐5A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferontreated cells. Proc Natl Acad Sci USA 1978; 75: 256–60
   PubMed Web of Science ®Google Scholar
• Affabris E, Romeo G, Belardelli F, Jemma C, Mechti N, Gresser I, et al. 2,5‐A synthetase activity does not increase in interferonresistant Friend leukemia cell variants treated with α/β interferon despite the presence of high‐affinity receptor sites. Virology 1983; 125: 508–12
   PubMed Web of Science ®Google Scholar
• Marti J, Vandebussche P, Silhol M, Milhaud P, Verhaegen M, Content J, et al. Effects of interferon on sensitive and resistant L 1210 cell lines. J Interferon Res 1981; 1: 287–95
   PubMedGoogle Scholar
• Salzberg S, Wreshner D H, Oberman F, Panet A, Bakhananshvili M. Isolation and characterization of an interferon‐resistant cell line deficient in the induction of (2',5') oligoadenylate synthetase activity. Mol Cell Biol 1983; 3: 1759–65
   PubMed Web of Science ®Google Scholar
• Silverman R H, Krause D, Jacobsen J, Leisy S A, Barlow D P, Friedman R M. 2,5‐A‐dependent RNase levels vary with interferon treatment, growth rate and cell differentiation. The biology of the interferon system, E DeMaeyer, H Schellekens. Elsevier, Amsterdam 1983; 189–200
   Google Scholar
• Tovey M G, Dron M, Mogensen K E, Lebleu B, Mechti N, Begon‐Lours‐Guymarho J. Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance. J Gen Virol 1983; 64: 2649–53
   PubMed Web of Science ®Google Scholar
• Grandér D, Öberg K, Lundqvist M ‐L, Janson Tiensuu E, Eriksson B, Einhorn S. Interferon‐induced enhancement of 2',5'‐oligoadenylate synthetase in mid‐gut carcinoid tumours. Lancet 1990; 336: 337–40
   PubMed Web of Science ®Google Scholar
• Rosenblum M G, Maxwell B L, Talpaz M. In vivo sensitivity and resistance of CML cells to α‐IFN; correlation with receptor binding and induction of 2',5'‐oligoadenylate synthetase. Cancer Res 1986; 46: 4848–52
   PubMed Web of Science ®Google Scholar
• Ferbus D, Khosravi S, Dumont J, Billard C. In vivo and in vitro induction of 2',5'‐oligoadenylate synthetase by interferon‐alpha in nodular non‐Hodgkin's lymphoma and correlations with the clinical response. J Biol Regul Homeostat Agents 1990; 4: 127–34
   PubMed Web of Science ®Google Scholar
• Einhorn S, Vanky F, Grandér D, Willems J. Induction of 2'‐5' oligoadenylate synthetase in malignant cells from freshly explanted tumor cells. Variability in the susceptibility to interferon. Eur J Cancer 1987; 23: 1607–13
   Web of Science ®Google Scholar
• Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–9
   PubMed Web of Science ®Google Scholar
• Widell A, Shev S, Månsson S, Zhang Y Y, Foberg U, Norkrans G, et al. Genotyping of hepatitis C virus isolates by a modified PCR assay using type specific primers: epidemiological applications. J Med Virol 1994; 44: 272–9
   PubMed Web of Science ®Google Scholar
• Chan S W, McOmish F, Holmes E C, Dow B, Peutherer J F, Follet E, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992; 73: 1131–41
   PubMed Web of Science ®Google Scholar
• Nousbaum J ‐B, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161–8
   PubMed Web of Science ®Google Scholar
• Gianelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2',5'‐oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993; 13: 57–60
   PubMedGoogle Scholar
• Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garruciu G, et al. Changes of serum 2',5'‐oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 1993; 13: 253–8
   PubMedGoogle Scholar
• Pawlotzky J M, Hovanessian A G, Roudot‐Thoraval F, Duvoux C, Bouvier M, Deforges L, et al. Is 2'‐5' oligoadenylate synthetase activity related to clinical response in to interferon therapy in patients with chronic hepatitis C? [abstract]. J Hepatol 1993; 18: 56
   Google Scholar
• Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA‐A,B,C and intracellular adhesion‐1 molecules. J Clin Invest 1995; 95: 2067–75
   PubMed Web of Science ®Google Scholar
• Pawlotzky J M, Hovanessian A G, Roudot‐Thoraval F, Duvoux C, Bouvier M, Deforges L, et al. The activity of the interferondependent enzyme 2'‐5' oligoadenylate synthetase in patients with chronic hepatitis C [abstract]. J Hepatol 1993; 18: 53
   PubMedGoogle Scholar
• Levy D E, Lew D J, Decker T, Kessler D S, Darnell J E. Synergistic interaction between interferon‐α and interferon‐γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 1990; 9: 1105–11
   PubMed Web of Science ®Google Scholar
• Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330: 143
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Watnabe S, Konishi M, Yokoi M, Kakehashi R, Kaitio M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon‐beta. Hepatology 1993; 18: 1319–25
   PubMedGoogle Scholar
• Foster G R, Achrill A M, Goldin R D, Kerr I M, Thomas H C, Stark G R. Expression of the terminal protein region of hepatitis B virus inhibits cellular response to interferons α and γ and doublestranded RNA. Proc Natl Acad Sci USA 1991; 88: 2888–92
   PubMed Web of Science ®Google Scholar
• Gutch M J, Reich N C. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci USA 1991; 88: 7913–7
   PubMed Web of Science ®Google Scholar